Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections

Table 3 Inflammation marker levels in patients treated with vancomycin (only) or vancomycin and teicoplanin

Group	Number of cases	PCT (ng/mL)	IL-1β (pg/mL)	TNF-α (pg/mL)	CRP (mg/L)	CPIS (point)
Before treatment
Study group	43	0.86 ± 0.23	223.37 ± 36.25	139.74 ± 23.65	91.39 ± 10.68	7.69 ± 2.88
Control group	43	0.91 ± 0.20	219.29 ± 35.56	142.91 ± 20.88	89.24 ± 12.29	8.01 ± 3.04
t value		1.076	0.527	0.659	0.866	0.501
P value		0.285	0.600	0.512	0.389	0.618
After treatment
Study group	43	0.28 ± 0.03	141.18 ± 18.62	41.46 ± 9.08	11.76 ± 4.43	2.19 ± 0.79
Control group	43	0.34 ± 0.05	163.53 ± 23.84	50.96 ± 10.35	18.25 ± 5.39	3.87 ± 1.01
t value		6.748	4.845	4.525	6.100	8.591
P value		0.000	0.000	0.000	0.000	0.000

CPIS: Clinical pulmonary infection score; CRP: C-reactive protein; IL -1β: Interleukin-1β; PCT: Procalcitonin; TNF-α: Tumor necrosis factor-α.